Cytokine Signalling Forum


L'upadacitinib améliore les résultats déclarés par les patients chez des patients atteints de polyarthrite rhumatoïde et une réponse inadéquate aux médicaments antirhumatismaux modificateurs de la maladie de synthèse conventionnels: résultats de SELECT-NEXT

Strand V, Pope J, Tundia N, Friedman A, Camp H, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M. - Arthritis Res Ther . 2019 Dec 9;21(1):272.

In SELECT-NEXT, UPA demonstrated clinically meaningful improvements in patient reported outcomes compared to PBO in patients with RA who had an inadequate response to csDMARDs. In this post hoc analysis, the effect of UPA 15 or 30 mg on patient reported outcomes were assessed and compared to PBO.
Eligible patients (661) with an inadequate response to csDMARDs were randomly assigned 2:2:1:1 to receive background csDMARD therapy with either UPA 15 mg, UPA 30 mg or PBO. PROs collected at Wk4 and Wk12 included patient global assessment of disease activity, HAQ DI, pain, fatigue, morning stiffness, work instability and SF-36. The percentage of patients with improvements in PROs greater than the minimum clinically important difference or scores greater than normative values were compared between UPA and PBO groups.
UPA 15 and 30 mg resulted in significant improvements compared to PBO in; patient global assessment of disease activity, pain, HAQ-DI, fatigue, SF-36 physical component summary, work instability and morning stiffness.
The authors concluded that UPA 15 or 30 mg once daily resulted in significant and clinically meaningful improvements in multiple aspects of QoL among csDMARD-IR patients with RA compared to PBO, through 12 weeks.

Mots clefs: JAK, Upadacitinib, Clinical, PRO

Access original article via Pubmed

Upload date: January 2020

Traduit par: Héléna Farese

Article image